Table 1.
Baseline demographics and disease characteristics
| PBO (N = 792) | ETN (N = 740) | IXE Q4W (N = 1165) | IXE Q2W (N = 1169) | |
|---|---|---|---|---|
| Age, years (SD) | 46.2 (12.8) | 45.5 (13.3) | 45.4 (13.1) | 45.1 (12.9) |
| Male, n (%) | 560 (70.7) | 505 (68.2) | 791 (67.9) | 766 (65.5) |
| Race, white, n (%) | 726 (91.7) | 682 (92.7) | 1072 (92.3) | 1092 (93.5) |
| Weight, kg (SD) | 91.6 (23.5) | 92.5 (23.4) | 92.1 (23.5) | 90.8 (22.7) |
| Body mass index, kg/m2 | 30.5 (7.2) | 31.0 (7.4) | 30.7 (7.2) | 30.4 (7.1) |
| Psoriasis duration, years (SD) | 19.1 (12.1) | 18.5 (12.1) | 18.9 (12.4) | 18.7 (12.1) |
| PASI (SD) | 20.57 (8.5) | 19.90 (7.5) | 20.40 (7.5) | 20.08 (7.9) |
| Itch NRS score, mean (SD) | 6.8 (2.6) | 6.4 (2.6) | 6.6 (2.6) | 6.8 (2.5) |
ETN etanercept, IXE ixekizumab, N number of patients in the analysis population, n number of patients in the specified category, NRS numeric rating scale, PBO placebo, Q2W once every 2 weeks, Q4W once every 4 weeks, SD standard deviation